A report on the blog FiercePharma says the approval of blood thinner Eliquis in Europe has the manufacturers of competing medications “on their toes.”
Eliquis, from Pfizer and Bristol-Myers Squibb, was developed as an alternative to warfarin, which for decades has been the standard treatment for blood clot prevention.
But according to FiercePharma, warfarin “comes with a host of dosage-tweaking rules, plus interactions with alcohol and food, so it is difficult ...
continue reading...The U.S. Food and Drug Administration has approved a new blood thinner manufactured by Pfizer Inc. and Bristol-Myers Squibb. A Bloomberg report describes Eliquis as a “potential blockbuster heart drug.”
The Food and Drug Administration cleared Eliquis for the prevention of blood clots that develop in patients with the heart rhythm disorder atrial fibrillation, after the manufacturers failed in two previous efforts to win approval for the drug.
It’s among a ...
continue reading...Regulators in Japan have approved the blood thinner Eliquis, the Japan Daily Times reports.
Eliquis is the brand name for apixaban, manufactured by Bristol-Myers Squibb Co and Pfizer Inc. It’s among a new class of blood thinners meant to replace decades-old warfarin, which is effective but can be difficult to use because it requires dietary restrictions and frequent testing.
Pharmaceutical companies have been looking to warfarin alternatives as potentially profitable areas ...
continue reading...The blood thinner Pradaxa has generated about $1.48 billion in worldwide sales over a span of less than two years. According to a story in Bloomberg, that’s largely because manufacturer Boehringer Ingelheim has been marketing it as a more convenient alternative to an existing medication.
Unlike the blood thinner warfarin, which has been around since the 1950s, Pradaxa does not require frequent blood testing and dietary restrictions.
But plaintiffs in numerous ...
continue reading...A new study is reporting good results for extended use of the blood thinner apixaban produced by Pfizer Inc. and Bristol-Myers Squibb Co.
A Reuters story says researchers found the drug, sold under brand name Eliquis, reduced the risk of recurrence of potentially deadly clots in the veins and lungs by 80 percent, with no increase in major bleeding.
Apixaban is among a new class of blood thinners meant to replace ...
continue reading...A Bloomberg report says German pharmaceutical company Boehringer Ingelheim GmbH is now facing more than 150 lawsuits over claims that the company sold the blood thinner Pradaxa despite being aware that it could cause potentially deadly bleeding.
Plaintiffs’ lawyers say the company will probably end up facing thousands more lawsuits in coming years. According to the story, the drug has been linked to ...
continue reading...
